aTyr Pharma | LIFE - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Ardelyx USD 89.66M 24.7M 2026-03
aTyr Pharma USD 987.07K 797.07K 2026-03
Biogen USD 2.12B 307M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Cipla INR 44.1B 5B 2026-06
Clal Biotechnology ILS -857K 1.42M 2022-06
Compugen USD 352K 63.44M 2026-03
CSL USD 4.46B 2.71B 2025-12
Curis USD 1.14M 8.86M 2025-12
GlaxoSmithKline GBP 6.51B 757M 2026-06
Grifols EUR 766.49M 39.74M 2024-12
Lakefront Biotherapeutics EUR 1.68M 898.68M 2026-03
Novartis USD 11.24B 1.18B 2026-06
Roche Holding CHF 22.69B 600M 2026-06
United Therapeutics USD 683.8M 35.7M 2026-06